Etrasimod in the Management of Eosinophilic Oesophagitis: Promising Results from the VOYAGE Phase 2 Trial

Study background and disease burden

Eosinophilic oesophagitis (EoE) is a chronic, immune-mediated inflammatory disease characterized by eosinophil-predominant inflammation of the oesophagus, leading to symptoms such as dysphagia and food impaction. The condition currently presents substantial unmet medical needs due to limited effective therapies and frequent reliance on off-label treatments like proton pump inhibitors (PPIs), topical corticosteroids, and esophageal dilation. Novel therapeutic agents targeting the underlying immune pathways are urgently needed to improve long-term disease control and patient quality of life.

Etrasimod is an oral, once-daily, selective modulator of sphingosine 1-phosphate (S1P) receptors 1, 4, and 5. By modulating lymphocyte trafficking and immunologic activity, etrasimod has shown efficacy in other immune-mediated inflammatory diseases. Given the immunopathology of EoE, the selective targeting of the S1P pathway represents a promising therapeutic approach.